Tradestie Institutional Equity Comparison Engine
BCAX vs TBPH โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TBPH Overall Edge
TBPH Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Theravance Biopharma, Inc. (TBPH) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus TBPH at 13.4x Forward P/E and 8.9% operating margin (-20.9% YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against TBPH sits in UNCLASSIFIED (16th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
TBPH
BCAX N/M vs TBPH 13.4x Fwd P/E
Growth & Margin Winner
TBPH
Op Margin 0.0% vs 8.9% ยท YoY +0.0% vs -20.9%
Momentum & Technical Winner
TBPH
1Y -31.6% vs +21.0% ยท 52W Pos 8% vs 50%
Options & Structure Winner
TBPH
BREAKDOWN (23rd %ile IV) vs UNCLASSIFIED (16th %ile IV)
BCAX
NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap
$665.2M
1M Return
-41.9%
1Y Return
-31.63%
Forward P/E
N/M
Unified AI Score
52.1 / 100
HOLD
Tech 58.0
Fund 66.0
Flow 68.0
Mom 64.0
TBPH
NASDAQ
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap
$884.2M
1M Return
+0.12%
1Y Return
+21.04%
Forward P/E
13.4x
Unified AI Score
54.9 / 100
HOLD
Tech 65.0
Fund 52.0
Flow 50.0
Mom 35.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BCAX -31.63%
TBPH +21.04%
Spread: +48.78 pp (BCAX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BCAX TTM Op. Margin: 0.0%
TBPH TTM Op. Margin: 8.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs TBPH. Trailing 12-month operating profitability (BCAX 0.0% vs TBPH 8.9%) and valuation multiples (BCAX N/M vs TBPH 13.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BCAX | TBPH | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $665.2M | $884.2M | Larger Scale | TBPH |
| Trailing P/E Ratio Valuation | N/M | 16.4x | Lower Multiple | TBPH |
| Forward P/E Ratio Valuation | N/M | 13.4x | Lower Multiple | TBPH |
| Revenue Growth (YoY) Growth | +0.0% | -20.9% | Higher Growth | BCAX |
| Operating Margin (TTM) Profitability | 0.0% | 8.9% | Higher Margin | TBPH |
| Net Profit Margin Profitability | 0.0% | 51.6% | Higher Margin | TBPH |
| Return on Equity (ROE) Capital Efficiency | -54.2% | 20.9% | Higher ROE | TBPH |
| 52-Week Range Position Momentum | 8% ($8โ$31) | 50% ($13โ$21) | Stronger Trend | TBPH |
| Beta / 30D Volatility Risk Regime | 1.42ฮฒ ยท 184% Vol | 0.48ฮฒ ยท 2% Vol | Lower Realized Risk | TBPH |
| Unified Institutional Score Composite Signal | 52.1 / 100 (HOLD) | 54.9 / 100 (HOLD) | Higher Composite | TBPH |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BCAX vs TBPH Buy Guide
BCAX
BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
TBPH
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BCAX nor TBPH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.